These studies suggest that CRLF2r and JAK2 mutations cooperate to drive leukaemogenesis (Russell et al., 2009; Tasian and Loh, 2011; Kim et al., 2018), a fact which could be exploited for therapeutic advantage in Ph-like ALL. Here, JAK2 is linked to acute lymphoblastic leukemia.